Clinical Trial Update: A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update indicating that B007 is being studied for Generalized Myasthenia Gravis in Phase 2/Phase 3, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• B007

Snippet

Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Conditions: Generalized Myasthenia Gravis | Phase 2, Phase 3 | Status: RECRUITING